Diabetes giant Novo Nordisk (NOV: N) looks set to maintain its dominant position in type 2 diabetes, despite recent supply issues affecting its glucagon-like peptide-1 (GLP-1) franchise.
Research from industry analyst GlobalData suggests that the launch of the firm’s oral GLP-1 agonist Rybelsus (semaglutide) could play a role in defending against rivals.
While sales have only increased slowly, the patient-friendly mode of administration provides a unique selling point in a congested market, adding to the firm’s established market share for the injectable Ozempic (semaglutide).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze